Alexion Pharma (ALXN) Tops Q4 EPS by 1c; Guides Below the Street, $1B Buyback Plan

Alexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $1.26, $0.01 better than the analyst estimate of $1.25. Revenue for the quarter came in at $831 million versus the consensus estimate of $836.6 million.

The Company also announced that its Board of Directors has increased the size of the Company's share repurchase authorization to a total of $1 billion. The Board’s authorization is open-ended.

GUIDANCE:

Alexion Pharma sees FY2017 EPS of $5.00-$5.25, versus the consensus of $5.54. Alexion Pharma sees FY2017 revenue of $3.4-3.5 billion, versus the consensus of $3.54 billion.

"In 2016 the global Alexion team delivered on our patient-centered objectives as we grew our leadership in complement by serving more patients with PNH and aHUS, and continued to build our metabolic franchise with the global launches of Strensiq and Kanuma. We also achieved important regulatory milestones towards new indications for Soliris and initiated two registration studies for ALXN1210 to drive our future growth,\" said David Brennan, Interim Chief Executive Officer of Alexion. \"Our 2017 guidance reflects double-digit revenue and EPS growth as we continue to grow our complement and metabolic franchises, prepare for the potential launches of Soliris in refractory gMG, and focus on our highest priority R&D programs.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• SBC Medical Group Holdings Incorporated (SBC) Misses Q2 EPS by 2c
• JD.com (JD) Tops Q1 EPS by 66c